Owens&Minor Investor Conference Presentation Deck

● ■ Adding approximately $1.2 billion of annual net revenue ▪ Adds in excess of $230 million in incremental adjusted EBITDA, implying -20% margin Annualized Financial Impact (Pre-Synergies) ▪ Annual capex requirements of ~$100 million ▪ FCF generation > $80 million Leverage Ratio to increase to just under 4x TTM adjusted EBITDA Expect to return to targeted leverage range of 2-3x within 24 months ■ • No changes to capital allocation priorities Deleverage the balance sheet - Re-invest organically in broader business to drive top-line growth / bottom-line efficiencies 9 Expect to change segment reporting structure beginning with 1Q22 filings - Patient Direct = Byram + Apria Products & Healthcare Services = Global Products + Medical Distribution and Services Transaction will be accretive to EPS in 2022 assuming 1H22 close - Combined Net Revenue ¹ (~$10.9B) 1 Combined numbers are non-GAAP and reflect the summation of OMI plus Apria, for FY 2021. See slide 2 for more information regarding OMI and Apria Combined measures and important limitations Patient Direct -20% Products & Healthcare Services -80% Combined Adjusted EBITDA¹ (~$725M) Products & Healthcare Services ~50% Patient Direct -50% Owens VI & Minor

View entire presentation